{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028761","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.633106+00:00","generated_at":"2026-06-22T03:53:16.782116+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bioventus Q3 net sales up 25.9% to $137.1M, but cuts full-year 2022 guidance sharply","bullets":["Q3 net sales $137.1M (+25.9% YoY); net income $3.2M vs net loss $2.3M prior year.","Adjusted EBITDA $22.7M (+$1.3M YoY); Non-GAAP EPS $0.08, down from $0.19 prior year.","Full-year 2022 guidance lowered: net sales $527-532M, Adj. EBITDA $75-79M, Non-GAAP EPS $0.20-0.25.","Debt increased to $424.4M from $357.7M at Dec 2021; cash $34.4M.","CEO highlights recent CartiHeal acquisition to enter large cartilage replacement market."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028761","json":"https://secwatch.observer/filing/0001628280-22-028761.json","markdown":"https://secwatch.observer/filing/0001628280-22-028761.md","text":"https://secwatch.observer/filing/0001628280-22-028761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022028761/0001628280-22-028761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022028761/bvs-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:53:16.782116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65fc432abbdf7161a5e490931f35ad1afc6c0d80","claim":"Bioventus Inc. reported three and nine months ended October 1, 2022 results: revenue $137.1 million, net income $3.2 million, EPS $0.03.","evidence_excerpt":"in innovations for active healing, today reported financial results for the three and nine months ended October 1, 2022. Q3 Financial Summary & Recent Highlights: • Net Sales of $137.1 million, up $28.2 million, or 25.9%, year-over-year as reported (26.8% constant currency*) and 7.3% organically* (8.1% constant currency*) • Net Income of $3.2 million, compared to Net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022028761/0001628280-22-028761-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended October 1, 2022"},{"label":"Revenue","value":"$137.1 million"},{"label":"Net income","value":"$3.2 million"},{"label":"EPS","value":"$0.03"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"daed08fbd2614ce63e3c2040eea68ec87a97635a","claim":"Bioventus Inc. reported twelve months ending December 31, 2022 results: revenue $527 million to $532 million, EPS $0.20 to $0.25. Guidance lowered.","evidence_excerpt":"Updated Full Year 2022 Financial Guidance: For the twelve months ending December 31, 2022, the Company now expects: • Net sales of $527 million to $532 million, representing year-over-year growth of approximately 22% to 23%, representing an update to the prior guidance of $547.5 million to $562.5 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022028761/0001628280-22-028761-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve months ending December 31, 2022"},{"label":"Revenue","value":"$527 million to $532 million"},{"label":"EPS","value":"$0.20 to $0.25"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}